We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
-5.21%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$265M
AUM Growth
+$15.2M
Cap. Flow
+$21.8M
Cap. Flow %
8.22%
Top 10 Hldgs %
65.9%
Holding
29
New
8
Increased
10
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$16.3M
2
CELC icon
Celcuity
CELC
+$12.7M
3
IRON icon
Disc Medicine
IRON
+$8.44M
4
INZY
Inozyme Pharma
INZY
+$5.53M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.95M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$10.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.33M
3
ANAB icon
AnaptysBio
ANAB
+$7.83M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.2M
5
GERN icon
Geron
GERN
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTNM
26
Contineum Therapeutics
CTNM
$577M
$1.28M 0.48%
+72,831
New +$1.17M
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
– –
-71,463
Closed -$4.2M
CABA icon
28
Cabaletta Bio
CABA
$450M
– –
-173,173
Closed -$2.95M
GERN icon
29
Geron
GERN
$1.01B
– –
-1,123,995
Closed -$3.71M
1
2

Similar funds

TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.32% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
BCM
Bienville Capital Management New York $550M AUM 3.49% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $549M AUM 24.44% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Saturn V Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Saturn V Capital Management held 29 positions worth $265M, up 6.1% from $249M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Saturn V Capital Management deployed $21.8M of net new capital in Q2 2024, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was CARGO Therapeutics: 856,849 shares worth $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $10.3M trimmed.

  • Saturn V Capital Management's largest Q2 2024 buy was CARGO Therapeutics: 856,849 shares worth $14.1M.
  • Saturn V Capital Management added most to Disc Medicine in Q2 2024, an estimated $8.44M increase.
  • Saturn V Capital Management's biggest Q2 2024 reduction was Merus, cutting an estimated $10.3M.
  • Saturn V Capital Management fully exited Apellis Pharmaceuticals in Q2 2024, selling an estimated $4.2M.
  • Saturn V Capital Management's ten largest holdings make up 66% of its $265M portfolio in Q2 2024.
  • Saturn V Capital Management opened 8 new positions and closed 3 in Q2 2024.
  • Saturn V Capital Management's portfolio value rose 6.1% quarter-over-quarter to $265M.

Based on Saturn V Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.